Benjamin George, MD, currently serving as the medical director of oncology at Community Hospital in McCook, Nebraska, and ...

A recent study reveals promising results for CLL patients using zanubrutinib and venetoclax, highlighting effective ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

Marija Balic, MD, discusses the design and mechanism of the Oncodetect tumor-informed circulating tumor DNA assay for ...

Marija Balic, MD, discusses challenges that remain to the widespread implementation of MRD-guided patient management in TNBC.

DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...

In a new observational study published in Cancer, commonly prescribed chronic medications did not affect the efficacy of ...

The MCED test shows similar performance in cancer survivors and the general population, with a PPV of 50% and high ...

During a live event, Kathryn E. Beckermann, MD, PhD, and participants discussed whether risk stratification factors into the ...

FOLFIRINOX chemotherapy is feasible in selected elderly patients with pancreatic ductal adenocarcinoma, though toxicity ...

Biomarker testing in non-small cell lung cancer is underutilized, hindering optimal treatment. Streamlined processes and ...

The FDA has granted breakthrough therapy designation (BTD) to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the ...